Proceedings of the 2016 China Cancer Immunotherapy Workshop

Bin Xue,Jiaqi Xu,Wenru Song,Zhimin Yang,Ke Liu,Zihai Li,Zihai Li,Lieping Chen,Edward B. Garon,Siwen Hu-Lieskovan,Wei Ding,Chong-Xian Pan,Weijing Sun,Yong-Jun Liu,Lei Zheng,Delong Liu,Michel Sadelain,Cassian Yee,Rongfu Wang,Meixia Chen,Yao Wang,Zhiqiang Wu,Hanren Dai,Can Luo,Yang Liu,Chuan Tong,Yelei Guo,Qingming Yang,Weidong Han,Lisa H. Butterfield,Timothy A. Chan,Wenru Song,Ruirong Yuan,Bo Lu,Ke Liu,Max Ning,Harald Enzmann,Heinz Zwierzina

DOI: https://doi.org/10.1186/s13045-016-0322-x

IF: 28.5

2016-01-01

Journal of Hematology & Oncology

Abstract:Table of contents A1 Proceedings of 2016 China Cancer Immunotherapy Workshop, Beijing, China Bin Xue, Jiaqi Xu, Wenru Song, Zhimin Yang, Ke Liu, Zihai Li A2 Set the stage: fundamental immunology in forty minutes Zihai Li A3 What have we learnt from the anti-PD-1/PD-L1 therapy of advanced human cancer? Lieping Chen A4 Immune checkpoint inhibitors in lung cancer Edward B. Garon A5 Mechanisms of response and resistance to checkpoint inhibitors in melanoma Siwen Hu-Lieskovan A6 Checkpoint inhibitor immunotherapy in lymphoid malignancies Wei Ding A7 Translational research to improve the efficacy of immunotherapy in genitourinary malignancies Chong-Xian Pan A8 Immune checkpoint inhibitors in gastrointestinal malignancies Weijing Sun A9 What’s next beyond PD-1/PDL1? Yong-Jun Liu A10 Cancer vaccines: new insights into the oldest immunotherapy strategy Lei Zheng A11 Bispecific antibodies for cancer immunotherapy Delong Liu A12 Updates on CAR-T immunotherapy Michel Sadelain A13 Adoptive T cell therapy: personalizing cancer treatment Cassian Yee A14 Immune targets and neoantigens for cancer immunotherapy Rongfu Wang A15 Phase I/IIa trial of chimeric antigen receptor modified T cells against CD133 in patients with advanced and metastatic solid tumors Meixia Chen, Yao Wang, Zhiqiang Wu, Hanren Dai, Can Luo, Yang Liu, Chuan Tong, Yelei Guo, Qingming Yang, Weidong Han A16 Cancer immunotherapy biomarkers: progress and issues Lisa H. Butterfield A17 Shaping of immunotherapy response by cancer genomes Timothy A. Chan A18 Unique development consideration for cancer immunotherapy Wenru Song A19 Immunotherapy combination Ruirong Yuan A20 Immunotherapy combination with radiotherapy Bo Lu A21 Cancer immunotherapy: past, present and future Ke Liu A22 Breakthrough therapy designation drug development and approval Max Ning A23 Current European regulation of innovative oncology medicines: opportunities for immunotherapy Harald Enzmann, Heinz Zwierzina